Skip to main content
ONCY
NASDAQ Life Sciences

Oncolytics Biotech Secures Key Patent for Pelareorep Manufacturing into 2044

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.877
Mkt Cap
$101.475M
52W Low
$0.54
52W High
$1.51
52W Position info
62% above low
Off High info
42% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

ONCY sits 62% above its 52-week low of $0.54.

Summary

Oncolytics Biotech announced a new U.S. patent protecting the commercial manufacturing process of its lead drug, pelareorep, until 2044, bolstering its intellectual property portfolio.


Key Events · Product Development and Regulatory · ONCY

  • New Manufacturing Patent Issued

    The USPTO issued a new patent protecting the proprietary manufacturing process for pelareorep, extending intellectual property protection until 2044.

  • Supports Commercial Scalability

    The patent is designed to ensure consistent production of pelareorep at commercial scale, a critical step as the company advances towards potential registration.

  • Bolsters IP Portfolio

    This adds to Oncolytics' growing intellectual property estate, which also includes a method-of-use patent application under review (protection into 2046 if issued) and plans for further filings in 2026.

  • Strategic Importance Amidst Financial Challenges

    The strengthening of pelareorep's IP is a positive development for the company, which recently reported a 'going concern' warning and is actively raising capital through an ATM program.


Analysis · ONCY · Life Sciences

This patent strengthens the intellectual property protection for pelareorep's commercial manufacturing process, extending it until 2044. For a clinical-stage biotech company like Oncolytics, which is advancing its lead asset towards potential commercialization and facing a 'going concern' warning, robust IP is critical for long-term value and future strategic partnerships. This development helps de-risk the asset and supports its commercial viability.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ONCY was trading at $0.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $101.5M. The 52-week trading range was $0.54 to $1.51. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ONCY - Latest Insights

ONCY
Nov 13, 2026, 4:16 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.370
Real-time Price: $0.3336 info
Change: -$0.0364 (-10%) info
Market Cap: $46.274M info
ONCY
Oct 27, 2026, 10:33 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.462
Real-time Price: $0.3336 info
Change: -$0.1284 (-28%) info
Market Cap: $46.274M info
ONCY
Sep 28, 2026, 9:32 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.6831
Real-time Price: $0.3336 info
Change: -$0.3495 (-51%) info
Market Cap: $46.274M info
ONCY
Sep 28, 2026, 9:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.6827
Real-time Price: $0.3336 info
Change: -$0.3491 (-51%) info
Market Cap: $46.274M info
ONCY
Aug 18, 2026, 9:05 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $0.8328
Real-time Price: $0.3336 info
Change: -$0.4992 (-60%) info
Market Cap: $46.274M info